English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, June 23, 2021
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma
Friday, June 18, 2021
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
エーザイとブリストル マイヤーズ スクイブ、エーザイ創製の抗体薬物複合体MORAb-202に関するグローバルな戦略的提携契約を締結
Tuesday, June 15, 2021
エーザイ、「Zonegran(R)」の欧州およびその他の地域の権利をAdvanz Pharma社に譲渡
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
Wednesday, June 9, 2021
エーザイ、第3回「プラチナキャリア・アワード」において特別賞を受賞
Eisai Receives Special Prize at Platinum Career Award 2021
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
Tuesday, June 8, 2021
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575